Clinical Trial Update: Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety, pharmacokinetics, and efficacy of KBSA301 for pneumonia due to Staphylococcus aureus has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia Due to Staphylococcus Aureus

Drugs mentioned

• KBSA301

Snippet

Sponsor: Aridis Pharmaceuticals, Inc. | Conditions: Pneumonia Due to Staphylococcus Aureus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-04-08